vildagliptin / Generic mfg. - LARVOL DELTA

Nano-liposomal berberine and vildagliptin combination: A novel therapeutic approach against oxidative stress, inflammation, autophagy dysregulation, and fibrosis in diabetic nephropathy. (PubMed, Tissue Cell) - "Histopathological examination supported these findings, showing significant improvement in kidney architecture. Together, our findings show that Vild and BHC-Lip work in concert to prevent DN through lowering oxidative stress and inflammation, boosting autophagy, and reducing renal structural damage."

Journal • Chronic Kidney Disease • Diabetes • Diabetic Nephropathy • Fibrosis • Immunology • Inflammation • Metabolic Disorders • Nephrology • Renal Disease • Type 2 Diabetes Mellitus • AKT1 • BECN1 • NES • VIM

Fluorescein-Based Charge-Transfer Fluorimetric Method for Quantification of Gliptin Drugs: Comprehensive Greenness, Blueness, and Sustainability Assessment. (PubMed, Luminescence) - "A green, sustainable, and highly sensitive fluorimetric method was developed for the quantitative determination of the antidiabetic agents alogliptin, saxagliptin, and vildagliptin in bulk powders and commercial formulations. Greenness and sustainability were evaluated using multiple assessment tools (AGSA, GAPI, AGREE, MoGAPI, Eco-scale, CACI, BAGI, CaFRI, and MA tool), confirming the eco-friendly profile of the assay. The proposed method provides a reliable, green alternative for routine quality control of gliptins in pharmaceutical preparations."

Journal

Comparative Evaluation of the Effects of Oral Anti-hyperglycemic Agents and an Ayurvedic Hepatoprotective Agent in a Rat Model of Non-alcoholic Fatty Liver Disease (NAFLD). (PubMed, Cureus) - "Baseline total cholesterol (TC), TG, aspartate aminotransferase (AST), and alanine aminotransferase (ALT) enzyme-linked immunosorbent assay (ELISA) was done, and then, all animals were divided into six groups (M = F) of six rats each (negative control - only high-fat diet, glimepiride group, vildagliptin group, dapagliflozin group, Liv52 group, and positive control - pioglitazone group, respectively) and fed with high-fat diet and water ad libitum for six weeks. Conclusion We conclude that glimepiride, which exhibited AST and ALT reductions along with a four-point NAS reduction, offers itself as a promising drug candidate for human clinical trials for MASLD. Vildagliptin, which exhibited TC, AST, and ALT reductions but a less promising one-point NAS reduction, can also be tried in human clinical trials for MASLD."

Journal • Preclinical • Diabetes • Fibrosis • Hepatology • Immunology • Inflammation • Metabolic Disorders • Metabolic Dysfunction-Associated Steatotic Liver Disease

Mechanism of vildagliptin-induced liver injury: An idiosyncratic drug reaction mediated by inflammasome activation. (PubMed, Int Immunopharmacol) - "These results indicate that vildagliptin-induced liver injury occurs via a mechanism whereby the covalent binding of vildagliptin induces the release of HSP40 from hepatocytes, in turn activating inflammasomes. We further demonstrated that the risk of vildagliptin-induced liver injury may be increased by impaired immune tolerance, such as that caused by the co-administration of immune checkpoint inhibitors."

Journal • Hepatology • Inflammation • Liver Failure • Oncology • DNAJB1 • IL1B

Dose-dependent effects of vildagliptin (DPP-4 inhibitor) in a scopolamine-induced memory impairment model in rats. (PubMed, Life Sci) - "These findings suggest that vildagliptin may exert protective effects against cognitive impairment by modulating cholinergic activity, inflammatory responses, and lipid peroxidation."

Journal • Preclinical • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Dementia • Diabetes • Metabolic Disorders • Oncology • Pain • Type 2 Diabetes Mellitus • IL1B • IL6 • TNFA

Endogenous Glucagon-Like Peptide 1 Enhanced by Vildagliptin Reduces Triglyceride Appearance During Intraduodenal Fat Infusion in Type 2 Diabetes. (PubMed, Diabetes) - "Fifteen participants with T2D, managed by diet and/or metformin, were studied on three occasions in a double-blind, randomized, crossover design. Vildagliptin selectively reduced TG(54:4) and TG(54:5) species, whereas exendin(9-39) increased total TGs and 10 individual TG species. The implications of our finding are that endogenous GLP-1 plays a physiological role in the regulation of postprandial lipid handling in T2D."

Journal • Cardiovascular • Diabetes • Dyslipidemia • Metabolic Disorders • Type 2 Diabetes Mellitus

Preclinical Modeling and Simulation to Explore the Tissue/Plasma Exposure and Pharmacodynamic Effect of Vildagliptin in Diabetes Treatment. (PubMed, CPT Pharmacometrics Syst Pharmacol) - "Although q12 h dosing interval reached 80% enzyme inhibition in plasma for > 25 mg doses, only the 100 mg reached this goal in muscle. The 92% enzyme inhibition was achieved in plasma for 50 and 100 mg q12 h but none of the dose regimens investigated reached this inhibition in tissues."

Journal • PK/PD data • Preclinical • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Genetic variants associated with glycemic and weight loss response to vildagliptin as add-on therapy to metformin in Egyptian obese type 2 diabetic patients: potential consequences on cardiac risk factors. (PubMed, Eur J Med Res) - "Glycemic control and body weight loss, and hence amelioration of Hcy level by Vilda as add-on therapy to Met in Egyptian T2DM obese patients are subjected to genetic variation in one or more of the DPP-4, GLP1R and KATP genes involved in Vilda's modes of action. The GG genotype for the three genes is associated with better glycemic response; however, the AA genotype of GLP1R is associated with better weight loss response. Gender has no effect; however, lower initialbody weight results in better glycemic and weight loss response."

Journal • Cardiovascular • Diabetes • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus • KCNJ11

Vildagliptin and Omarigliptin Differentially Bind to DPP-4 Homodimers and Modulate Osteoclast-Mediated Bone Resorption. (PubMed, Compr Physiol) - "In conclusion, DPP-4 inhibitors could improve bone microstructure, in part by increasing osteoblast viability and inhibiting osteoclast-mediated bone resorption. Thus, omarigliptin may offer greater benefits to diabetic patients with osteoporosis, as it also helps suppress osteoclastogenesis and bone resorption."

Journal • Diabetes • Metabolic Disorders • Musculoskeletal Diseases • Orthopedics • Osteoporosis • Rheumatology • CTSK • RUNX2

Biopolymeric Zein Protein Nanoparticles for Oral Vildagliptin Delivery: Fabrication, Statistical Optimization, and In Vivo Pharmacokinetics and Pharmacodynamics Insights. (PubMed, AAPS PharmSciTech) - "These findings indicated improved oral bioavailability and prolonged residence time of VLD. Additionally, the in vivo pharmacodynamic study revealed that F04 provided markedly superior and sustained hypoglycemic effects over the marketed VLD product, with higher Rmax, longer TR½, and a 2.8-fold increase in AUC(0-24H)."

Journal • PK/PD data • Preclinical • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Trends in Adverse Event Reports of Dipeptidyl Peptidase-4 Inhibitor-Associated Pemphigoid in Japan. (PubMed, Drugs Real World Outcomes) - "The number of reported DPP-4 inhibitor-associated pemphigoid events increased after the revised precautions of package inserts for DPP-4 inhibitors were released."

Adverse events • Journal • Diabetes • Immunology • Metabolic Disorders • Type 2 Diabetes Mellitus

Comparative Effect of SGLT2 Inhibitors and GLP-1 Agonists on Glycemic Control in Type 2 Diabetes Mellitus. (PubMed, J Pharm Bioallied Sci) - "They were randomly given either empagliflozin, Canagliflozin, Dapagliflozin, Ertugliflozin, Bexagliflozin, Sotagliflozin (an SGLT2 inhibitor) or liraglutide, Sitagliptin, Saxagliptin, Linagliptin, Alogliptin, Vildagliptin (n GLP-1 receptor agonist) to consume for 24 weeks. But GLP-1 agonists are better at helping people lose weight and keep their hearts healthy, so they are also a fantastic choice for people who have these problems. It's crucial to consider what each patient needs and what could go wrong while establishing treatment plans for them."

Journal • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Cardiovascular Disease and Diabetes: A New Challenge in the Treatment and Management. (PubMed, Int J Mol Sci) - "The latest classes of glucose-lowering drugs introduced in the clinical practice are DPP4 inhibitors (sitagliptin, saxagliptin, vildagliptin, linagliptin, and alogliptin), GLP-1 receptor agonists (semaglutide, liraglutide, albiglutide, dulaglutide, exenatide, and lixenatide), and SGLT-2 inhibitors (empaglifozin, canaglifozin, and dapaglifozin). Multiple lines of evidence show that all these new drugs associated with the treatment of diabetic disease have the same effectiveness as the traditional antidiabetic drugs, and excellent cardiovascular safety, highlighting their potential in significantly reducing major cardiovascular events and mortality. The aim of our review is to summarise the clinical efficacy of these recently introduced drugs to optimise treatment strategies, especially in the early phase of diabetic disease."

Journal • Review • Cardiovascular • Diabetes • Metabolic Disorders

Vildagliptin-Induced Bullous Pemphigoid: A Retrospective Cohort Study. (PubMed, Australas J Dermatol) - "Non-vildagliptin BP was more likely to require systemic immunosuppression. Vildagliptin-induced BP represents a common and under-recognised clinical entity in New Zealand."

Journal • Retrospective data • Bullous Pemphigoid • Dermatology • Dermatopathology • Immunology

Association Between DPPs-4 Inhibitors and Bullous Pemphigoid: Reporting Odds Ratio Analysis Using EudraVigilance Database. (PubMed, Pharmaceuticals (Basel)) - "The predominant factors in the case/exposure group were male gender (58.6%), age between 65 and 85 years (43.3%), medical history of type 2 diabetes mellitus (30.4%) and consumption of vildagliptin (44.2%)...Disproportionality measures were estimated to be higher in the exposure group than in the positive controls. As such, BP could appear after several months of exposure, and dermatological monitoring is crucial."

Journal • Bullous Pemphigoid • Dermatology • Dermatopathology • Developmental Disorders • Diabetes • Immunology • Metabolic Disorders • Type 2 Diabetes Mellitus

Effectiveness and Safety of a Fixed-Dose Combination of Dapagliflozin and Vildagliptin in the Treatment of Type 2 Diabetes Mellitus: A Retrospective Study. (PubMed, Cureus) - "The FDC was well tolerated, with no serious AEs and only mild, self-limiting side effects. Conclusions This retrospective, single-center, short-term study suggests that dapagliflozin 5 mg and vildagliptin 50 mg may improve glycemic control in patients with T2DM over a three-month period; however, larger, long-term studies are required to confirm durability and safety."

Journal • Retrospective data • Diabetes • Hypoglycemia • Infectious Disease • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus • Urology

CD26 as a potential therapeutic target for lung adenocarcinoma. (PubMed, Front Oncol) - "In vitro, treatment with vildagliptin reduced the expression of Vimentin and the capacity for colony formation in H460 and LLC cell lines. The correlation of CD26 expression in lung adenocarcinomas and better patient survival, the antiproliferative effect on tumor cells by CD26 inhibition, and an altered EMT status give rise to the hypothesis that CD26 inhibitors impact the biology and clinical course of lung adenocarcinomas."

Journal • Lung Adenocarcinoma • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma • CDH1 • DPP4 • VIM

Hepatoprotective role of vildagliptin in CLP-induced sepsis in mice. (PubMed, Wiad Lek) - " Vildagliptin has Hepatoprotective effect during endotoxemia induced liver injury through modulation inflammatory and oxidative stress markers in addition to down regulation of Wnt/B-catenin pathway."

Journal • Preclinical • Hepatology • Infectious Disease • Liver Failure • Septic Shock • ICAM1 • IL6 • MAP1A • MIF

Vildagliptin-Associated Acquired Hemophilia A. (PubMed, Ann Pharmacother) - No abstract available

Journal • Hematological Disorders • Hemophilia • Hemophilia A • Rare Diseases

Dipeptidyl Peptidase 4 Inhibitors: Novel Therapeutic Agents in the Management of Type II Diabetes Mellitus. (PubMed, Pharmacoepidemiol Drug Saf) - "DPP-4 inhibitors remain effective and well-tolerated options for managing T2DM."

Journal • Review • Diabetes • Hypoglycemia • Metabolic Disorders • Type 2 Diabetes Mellitus

Exploring the Evidence for Personalized Pharmacotherapy in Type 2 Diabetes-A Systematic Review. (PubMed, J Pers Med) - " We systematically searched PubMed, Scopus, and Web of Science for studies published from the earliest available records to 18 August 2025 using the following Boolean search terms: "miRNA AND gliclazide", "miRNA AND glibenclamide", "miRNA AND gliquidone", "miRNA AND glimepiride", "mirRNA AND metformin", "miRNA AND pioglitazone", "miRNA AND rosiglitazone", "miRNA AND sitagliptin", "miRNA AND vildagliptin", "miRNA AND alogliptin", "miRNA and saxagliptin", "miRNA AND linagliptin", "miRNA AND liraglutide", "miRNA and dulaglutide", "miRNA AND semaglutide", "miRNA AND tirzepatide", "miRNA AND lixisenatide", "miRNA AND empagliflozin", "miRNA AND dapagliflozin", miRNA AND insulin glargine", "miRNA AND insulin detemir", "miRNA AND insulin degludec", "miRNA AND..."

Journal • Review • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Development and Validation of High-Performance Thin Layer Chromatographic Method for the Simultaneous Estimation of Dapagliflozin and Vildagliptin in Fixed-Dose Combination. (PubMed, Turk J Pharm Sci) - "The proposed HPTLC method allows for the simultaneous estimation of DAP and VIL with high accuracy, precision, and sensitivity. Owing to its satisfactory analytical performance, the method is suitable for routine quality control of combined dosage forms containing DAP and VIL."

Journal • Diabetes • Metabolic Disorders

Synthesis and Toxicological Evaluation of N-Nitroso Vildagliptin Amide Impurity in BALB 3T3 Clone Cells. (PubMed, J Appl Toxicol) - "These findings confirm that NNVI presents a toxicological risk at concentrations above regulatory limits. The study underscores the importance of strict impurity control in pharmaceutical formulations and contributes to the wider effort of ensuring drug safety by limiting nitrosamine exposure to acceptable thresholds."

Journal • CAT

Gliptin-Induced Bullous Pemphigoid: Are Statins and Angiotensin Receptor Blockers the Cause? (PubMed, Dermatol Ther (Heidelb)) - "This is one of the first studies to compare demographic, clinical, and laboratory characteristics of patients with gliptin-induced and conventional BP. Our results suggest gliptin-associated BP may present with more severe disease. Hyperlipidemia, ARB, and statin use may be associated with DPP4i-induced BP. Although larger studies are warranted to confirm this association, we believe these findings should be kept in mind while choosing patients to treat with gliptins."

Journal • Bullous Pemphigoid • Cardiovascular • Dermatology • Dermatopathology • Diabetes • Dyslipidemia • Hypertension • Immunology • Metabolic Disorders

Bioanalytical Method Development and Validation for the Estimation of Metformin and Vildagliptin in K3EDTA Human Plasma Using HPLCESI- MS/MS. (PubMed, Drug Metab Bioanal Lett) - "The aforementioned technique is reliable and effective for monitoring bioequivalence investigations in human participants."

Journal